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Objectives: Surveillance studies can identify patterns
of resistance and assist in empiric antibiotic choices as
resistance can vary by organism and body site isolation.
The Tigecycline Evaluation Surveillance Trial (T.E.S.T.) is
an ongoing global study that can serve to help recognize
resistance by body site. This report evaluates differences in
susceptibility of strains from different body sites, collected
in Asia/Paciﬁc Rim 2004—2007.
Methods: 4057 strains isolated from 8 specimen types
were collected and identiﬁed from 2004 to 2007 at 23
hospitals in 9 countries in Asia/Paciﬁc Rim. MICs for each
strain were determined per CLSI guidelines at each facil-
ity using broth microdilution. MIC50/90 values were analyzed
to identify any signiﬁcant differences in antibiograms from
different sources.
Results: Tigecycline (TIG) MIC50 values for almost all
organism/specimen pairings were ±2 dilutions of each other,
with no single source giving a higher MIC50 than others. The
same was seen for TIG MIC90 values, which were almost
always within 1—2 dilutions of the MIC50. Comparator drugs
generally showed similar absence of variability in activity vs.
isolates from various body sites; however, their MIC90/MIC50
ratios were usually much higher than those of TIG. Even
imipenem had such high ratios with Acinetobacter and Ente-
rococus spp.
Conclusions: Bacteria isolated from more than 10 differ-
ent body sites had generally similar antibiograms, with no
single source showing signiﬁcantly different sensitivity pat-
terns. TIG demonstrated a broad spectrum of activity and
consistently low MIC90/50 ratios, including strains resistant to
other drugs (MRSA, ESBL-producers, and imipenem-resistant
Acinetobacter).
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Objectives: Tigecycline (TIG), a new glycylcycline, has
been shown to have potent broad spectrum activity against
most commonly encountered species responsible for com-
munity and hospital acquired infections. The T.E.S.T.
program determined the in vitro activity of TIG and 10
comparators against bacteremia pathogens. Isolates were
collected from 9 hospital sites in Australia throughout
2004—2007.
Methods: 533 bacteremia isolates were identiﬁed to the
species level at participating sites and conﬁrmed by the cen-
tral laboratory. MICs were determined by each site using
supplied broth microdilution panels and interpreted accord-
ing to CLSI guidelines.
Results: Susceptibility of selected pathogens to tigecy-
cline is summarized below.
Conclusions: TIG demonstrated a broad spectrum of
antimicrobial activity, including Acinetobacter spp., Enter-
obacteriaceae (incl. ESBL phenotypes), S. aureus (incl.
MRSA), S. pneumoniae (all phenotypes), and both Van-S
and Van-R Enterococcus spp. The wide spectrum of activ-
ity of tigecycline provides enhanced antimicrobial coverage
of pathogens causing bacteremia.
doi:10.1016/j.ijid.2008.05.1073
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Objectives: Tigecycline (TIG) is the ﬁrst member of
the glycylcycline class of anti-infectives to be marketed,
exhibiting a broad spectrum of antibacterial activity against
many commonly-isolated pathogens. This study evaluates
the in vitro activity of TIG versus levoﬂoxacin (LEV)-resistant
strains in a large set of isolates collected globally from
2004—2007.
Methods: 4,335 LEV-resistant isolates were identiﬁed to
the species level at participating sites and conﬁrmed by the
central laboratory. MICs were determined by each site using
supplied broth microdilution panels and interpreted accord-
ing to CLSI guidelines.
Results: Percentages of LEV-resistant isolates susceptible
to TIG are summarized in the table below.
Conclusions: LEV resistance was rare in this study, with
less than 1% observed among the species evaluated. When
resistance to LEV was seen, however, TIG retained activity
in the vast majority of such strains. TIG’s broad spectrum of
activity, including strains resistant to other drugs, makes it a
valuable tool for treating serious infections caused by bacte-
ria that may be refractory to treatment with commonly-used
antimicrobials such as LEV.
doi:10.1016/j.ijid.2008.05.1074
